Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Peripheral T-Cell Lymphoma (PTCL)”

192 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 192 results

Early research (Phase 1)Study completedNCT02809573
What this trial is testing

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Who this might be right for
Peripheral T-cell Lymphoma
Chipscreen Biosciences, Ltd. 30
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Testing effectiveness (Phase 2)Study completedNCT01456039
What this trial is testing

A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Lymphoma, T-cell, Peripheral
Celgene 51
Early research (Phase 1)Study completedNCT01689220
What this trial is testing

SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

Who this might be right for
Peripheral T-cell Lymphoma
Solasia Pharma K.K. 6
Early research (Phase 1)Ended earlyNCT02978235
What this trial is testing

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Who this might be right for
Multiple MyelomaNonHodgkin Lymphoma
Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)UnknownNCT04480125
What this trial is testing

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Who this might be right for
Peripheral T-cell Lymphoma
Ruijin Hospital 28
Testing effectiveness (Phase 2)Study completedNCT04569032
What this trial is testing

Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Who this might be right for
Peripheral T-cell Lymphoma
Seagen, a wholly owned subsidiary of Pfizer 82
Early research (Phase 1)Active Not RecruitingNCT02732275
What this trial is testing

DS-3201b in Participants With Lymphomas

Who this might be right for
Lymphoma, MalignantNon-hodgkin Lymphoma
Daiichi Sankyo Co., Ltd. 100
Testing effectiveness (Phase 2)UnknownNCT02495415
What this trial is testing

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T-cell Lymphoma
CerRx, Inc. 140
Early research (Phase 1)Looking for participantsNCT04234048
What this trial is testing

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Who this might be right for
T-cell LymphomaCutaneous/Peripheral T-Cell LymphomaPeripheral T-cell Lymphoma+8 more
SciTech Development, Inc. 46
Testing effectiveness (Phase 2)Ended earlyNCT00972842
What this trial is testing

Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)

Who this might be right for
Peripheral T-Cell Non-Hodgkin's Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 20
Testing effectiveness (Phase 2)Study completedNCT02497131
What this trial is testing

Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients

Who this might be right for
Lymphatic Diseases
Fondazione Italiana Linfomi - ETS 25
Early research (Phase 1)Not Yet RecruitingNCT06712173
What this trial is testing

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 33
Early research (Phase 1)Ended earlyNCT00671112
What this trial is testing

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Who this might be right for
714leukemiaLymphoma
Brian Hill, MD, PhD 30
Early research (Phase 1)Study completedNCT05225584
What this trial is testing

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Who this might be right for
Non Hodgkin Lymphoma (NHL)Peripheral T-cell Lymphoma (PTCL)Cutaneous T-Cell Lymphoma (CTCL)+3 more
Kymera Therapeutics, Inc. 56
Early research (Phase 1)Study completedNCT02567656
What this trial is testing

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Who this might be right for
Lymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous
Rhizen Pharmaceuticals SA 58
Early research (Phase 1)Study completedNCT00355472
What this trial is testing

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

Who this might be right for
Adult T-Cell Leukemia and Lymphoma (ATL)Adult Peripheral T-Cell Lymphoma (PTCL)
Kyowa Kirin Co., Ltd. 16
Not applicableAvailableNCT04809233
What this trial is testing

Expanded Access to Tipifarnib

Who this might be right for
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Kura Oncology, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT05931263
What this trial is testing

Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL

Who this might be right for
Newly Diagnosed Peripheral T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University 104
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06757387
What this trial is testing

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Who this might be right for
Peripheral T-cell Lymphoma
Peking University Cancer Hospital & Institute 45
Next Page